X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs SUN PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA SUN PHARMA GLENMARK PHARMA/
SUN PHARMA
 
P/E (TTM) x 16.6 24.9 66.5% View Chart
P/BV x 2.9 2.6 111.9% View Chart
Dividend Yield % 0.4 0.5 74.3%  

Financials

 GLENMARK PHARMA   SUN PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
SUN PHARMA
Mar-18
GLENMARK PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs930701 132.8%   
Low Rs517433 119.4%   
Sales per share (Unadj.) Rs322.6110.4 292.2%  
Earnings per share (Unadj.) Rs28.511.0 259.5%  
Cash flow per share (Unadj.) Rs39.217.2 227.5%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.30.4 78.3%  
Book value per share (Unadj.) Rs183.0158.8 115.2%  
Shares outstanding (eoy) m282.172,399.26 11.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.25.1 43.7%   
Avg P/E ratio x25.451.6 49.2%  
P/CF ratio (eoy) x18.532.9 56.1%  
Price / Book Value ratio x4.03.6 110.8%  
Dividend payout %7.018.2 38.5%   
Avg Mkt Cap Rs m204,2061,360,021 15.0%   
No. of employees `00013.717.8 77.1%   
Total wages/salary Rs m18,71853,671 34.9%   
Avg. sales/employee Rs Th6,636.814,890.9 44.6%   
Avg. wages/employee Rs Th1,364.73,017.1 45.2%   
Avg. net profit/employee Rs Th586.11,480.6 39.6%   
INCOME DATA
Net Sales Rs m91,031264,895 34.4%  
Other income Rs m9148,388 10.9%   
Total revenues Rs m91,945273,282 33.6%   
Gross profit Rs m16,15456,081 28.8%  
Depreciation Rs m3,01914,998 20.1%   
Interest Rs m2,8565,176 55.2%   
Profit before tax Rs m11,19344,295 25.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m3,1558,452 37.3%   
Profit after tax Rs m8,03926,338 30.5%  
Gross profit margin %17.721.2 83.8%  
Effective tax rate %28.219.1 147.7%   
Net profit margin %8.89.9 88.8%  
BALANCE SHEET DATA
Current assets Rs m69,887316,359 22.1%   
Current liabilities Rs m32,879198,643 16.6%   
Net working cap to sales %40.744.4 91.5%  
Current ratio x2.11.6 133.5%  
Inventory Days Days8195 85.9%  
Debtors Days Days93108 86.8%  
Net fixed assets Rs m28,892213,178 13.6%   
Share capital Rs m2822,399 11.8%   
"Free" reserves Rs m51,353378,606 13.6%   
Net worth Rs m51,635381,006 13.6%   
Long term debt Rs m41,41817,721 233.7%   
Total assets Rs m125,954643,028 19.6%  
Interest coverage x4.99.6 51.5%   
Debt to equity ratio x0.80 1,724.6%  
Sales to assets ratio x0.70.4 175.4%   
Return on assets %8.64.9 176.5%  
Return on equity %15.66.9 225.2%  
Return on capital %15.110.0 150.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31740,816 89.0%   
Fx outflow Rs m9,72030,143 32.2%   
Net fx Rs m26,59810,673 249.2%   
CASH FLOW
From Operations Rs m16,48139,072 42.2%  
From Investments Rs m-10,133-33,708 30.1%  
From Financial Activity Rs m-4,685-15,393 30.4%  
Net Cashflow Rs m1,770-7,359 -24.1%  

Share Holding

Indian Promoters % 48.3 63.7 75.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 5.1 134.5%  
FIIs % 34.4 23.0 149.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.3 126.5%  
Shareholders   56,727 133,026 42.6%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  ELDER PHARMA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)

Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


May 24, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS